<< Back to News

System Formulary Update
Oral Oncolytic Agents (Part II)

Situation

The oral oncolytic agents class review and formulary standardization (Part II) was approved by the System Pharmacy & Therapeutics Committee in May 2022.

Background

The following medications were reviewed: exemestane (Aromasin); imatinib (Gleevec); temozolomide (Temodar); venetoclax (Venclexta); ruxolitinib (Jakafi)

Assessment/Recommendation

Changes effective: Tuesday, June 28^th

System P&T voted to include the following products on the UNC Health Care System Drug Formulary:

• Exemestane (Aromasin) 25 mg tablets.
• Imatinib (Gleevec) 100 mg tablets. Orders must be signed by a Hematology/Oncology Attending Physician.
• Temozolomide (Temodar) 20 mg and 100 mg capsules. Orders must be signed by a Hematology/Oncology Attending Physician.
• Venetoclax (Venclexta) 100 mg tablets. Use is restricted to initiation in patients with acute myeloid leukemia (AML), and orders must be signed by a Hematology/Oncology Attending Physician.
• Ruxolitinib (Jakafi) 5 mg and 10 mg tablets. Orders must be signed by a Hematology/Oncology Attending Physician.

System P&T voted to exclude the following products on the UNC Health Care System Drug Formulary:

• Imatinib (Gleevec) 400 mg tablets.
• Temozolomide (Temodar) 5 mg, 140 mg, and 250 mg capsules.
• Venetoclax (Venclexta) 10 mg and 50 mg tablets.
• Ruxolitinib (Jakafi) 20 mg tablets.

Note: Stock of these formulary products may vary at individual entities